The literature, as mentioned earlier, suggests that IL-6 and IL-1β play a prominent role in the pathogenesis and severity of COVID-19, and that is why the IL-6 and IL1β antagonists are in a clinical trial [49]. The gene discussed is IL1B; the disease is COVID-19.